AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the production of phosphoric acid from phosphate rock, calcium phosphate is treated with sulfuric acid and calcium sulfate precipitates. The product, called phosphogypsum is often contaminated with impurities making its use uneconomic. In the production of hydrogen fluoride, calcium fluoride is treated with sulfuric acid, precipitating calcium sulfate. In the refining of zinc, solutions of zinc sulfate are treated with hydrated lime to co-precipitate heavy metals such as barium. Calcium sulfate can also be recovered and re-used from scrap drywall at construction sites. These precipitation processes tend to concentrate radioactive elements in the calcium sulfate product. This issue is particular with the phosphate by-product, since phosphate ores naturally contain uranium and its decay products such as radium-226, lead-210 and polonium-210. Extraction of uranium from phosphorus ores can be economical on its own depending on prices on the uranium market or the separation of uranium can be mandated by environmental legislation and its sale is used to recover part of the cost of the process. Calcium sulfate is also a common component of fouling deposits in industrial heat exchangers, because its solubility decreases with increasing temperature (see the specific section on the retrograde solubility).
The following year, Pauling published what he regarded as his most important paper, in which he first laid out the concept of hybridization of atomic orbitals and analyzed the tetravalency of the carbon atom. At Caltech, Pauling struck up a close friendship with theoretical physicist Robert Oppenheimer at the University of California, Berkeley, who spent part of his research and teaching schedule as a visitor at Caltech each year. Pauling was also affiliated with Berkeley, serving as a visiting lecturer in physics and chemistry from 1929 to 1934. Oppenheimer even gave Pauling a stunning personal collection of minerals. The two men planned to mount a joint attack on the nature of the chemical bond: apparently Oppenheimer would supply the mathematics and Pauling would interpret the results. Their relationship soured when Oppenheimer tried to pursue Pauling's wife, Ava Helen. When Pauling was at work, Oppenheimer came to their home and blurted out an invitation to Ava Helen to join him on a tryst in Mexico. She flatly refused, and reported the incident to Pauling. He immediately cut off his relationship with Oppenheimer. In the summer of 1930, Pauling made another European trip, during which he learned about gas-phase electron diffraction from Herman Francis Mark. After returning, he built an electron diffraction instrument at Caltech with a student of his, Lawrence Olin Brockway, and used it to study the molecular structure of a large number of chemical substances. Pauling introduced the concept of electronegativity in 1932.
The hunting of American black bears has taken place since the initial peopling of the Americas. The first piece of evidence dates to a Clovis site at Lehner Ranch, Arizona. Partially calcined teeth of a 3-month old black bear cub came from a roasting pit, suggesting the bear cub was eaten. The surrounding charcoal was dated to the Early Holocene (10,940 BP). Black bear remains also appear to be associated with early peoples in Tlapacoya, Mexico. Native Americans increasingly utilized black bears during the Holocene, particularly in the late Holocene upper Midwest, e.g., Hopewell and Mississippian cultures. Some Native American tribes, in admiration for the American black bear's intelligence, would decorate the heads of bears they killed with trinkets and place them on blankets. Tobacco smoke would be wafted into the disembodied head's nostrils by the hunter that dealt the killing blow, who would compliment the animal for its courage. The Kutchin typically hunted American black bears during their hibernation cycle. Unlike the hunting of hibernating grizzly bears, which was fraught with danger, hibernating American black bears took longer to awaken and hunting them was thus safer and easier. During the European colonization of eastern North America, thousands of bears were hunted for their meat, fat and fur. Theodore Roosevelt wrote extensively on black bear hunting in his Hunting the Grisly and other sketches, in which he stated,
Sources: en.wikipedia.org
== Nutrition == A baseball steak per ounce contains 57 calories, 3 grams of fat, and 6 grams of protein. Like other red meats it also contains iron, creatine, minerals such as zinc and phosphorus, and B-vitamins: (niacin, vitamin B12, thiamin, riboflavin), and lipoic acid.
==== Modi–Trump relationship (2025–present) ==== On July 30, 2025, US President Donald Trump announced that Indian products would be subject to 25% tariffs upon arrival in the United States starting August 1, and that a "penalty" would be added for the purchase of Russian oil.
=== Rate of flow === Rate of blood flow varies greatly between different organs. Liver has the most abundant blood supply with an approximate flow of 1350 ml/min. Kidney and brain are the second and the third most supplied organs, with 1100 ml/min and ~700 ml/min, respectively. Relative rates of blood flow per 100 g of tissue are different, with kidney, adrenal gland and thyroid being the first, second and third most supplied tissues, respectively.
Sources: en.wikipedia.org
=== Primary lymphoid organs === The primary (or central) lymphoid organs, including the thymus, bone marrow, fetal liver, and yolk sac, are responsible for generating lymphocytes from immature progenitor cells in the absence of antigens. The thymus and the bone marrow constitute the primary lymphoid organs involved in the production and early clonal selection of lymphocyte tissues. Bird species' primary lymphoid organs include the bone marrow, thymus, bursa of Fabricius, and yolk sac.
=== Sleepwalking and complex sleep behaviors === Zolpidem is associated with complex sleep behaviors (CSBs), defined as activities performed during sleep followed by amnesia. These activities may include walking, driving, eating, having sex, having conversations, and performing other daily activities while asleep. Research by Australia's National Prescribing Service found these activities typically occur after the first dose or within a few days of starting therapy, although they may occur at any time during treatment. Concerns regarding zolpidem-related CSBs have prompted actions by regulatory authorities, including Australia's Therapeutic Goods Administration (TGA) and the U.S. Food and Drug Administration (FDA). In February 2008, the TGA implemented a boxed warning for the drug. In April 2019, the FDA strengthened the drug's warning labeling by adding a black box warning highlighting the risk of serious injuries and fatalities related to CSBs, even at recommended doses and after single use, and added a contraindication advising against zolpidem use in patients with a history of CSBs.
14 November RVNAF fighter-bombers supporting ARVN forces at Bu Prang Camp hit both ARVN and PAVN forces in an airstrike killing 20 ARVN and an estimated 95 PAVN. Police used tear gas against protesters marching on the South Vietnamese embassy in Washington D.C. and arrested 30 protesters.
== External links == Official website (Archived) Theranos Original Pitchdeck 2006, "A Presentation for Investors" "Elizabeth Holmes on Her Billion-Dollar Health Care Idea", Charlie Rose via YouTube, June 3, 2015. Tobak, Steve, "After the Theranos Mess, Can We Finally Quit Idolizing Entrepreneurs?" (Commentary), Fortune magazine. May 27, 2016. "Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud" (Press release). The Securities and Exchange Commission. Retrieved March 14, 2018. Theranos' Fatal Flaws Were in Plain Sight, Barry Ritholz. Bloomberg Opinion. 31 May 2018. The Rise and Fall of Elizabeth Holmes, Avery Hartmans. Business Insider Australia. April 21, 2018.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.